Ozempic Alternatives: Affordable Weight Loss Medications in 2026

Ozempic is expensive and hard to find. Here are the best alternatives for weight loss in 2026, including Wegovy, Mounjaro, Zepbound, and compounded semaglutide.

Majesta Health Medical TeamMedically Reviewed
Reviewed May 1, 20267 min read

If you've tried to get Ozempic recently, you know the struggle. Between shortages, insurance hurdles, and a price tag of nearly $1,000 per month, getting this medication has become increasingly difficult.

The good news? There are effective alternatives, some of which are more affordable and more accessible than Ozempic itself. Here's a complete guide to your options in 2026.

First, What Is Ozempic?

Ozempic is a brand-name medication containing semaglutide, FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Its popularity has led to nationwide shortages and skyrocketing prices.

Your Ozempic Alternatives

### 1. Wegovy Wegovy contains the same active ingredient as Ozempic (semaglutide) at a higher dose specifically approved for weight loss.

  • Cost: $1,349/month without insurance
  • How it's taken: Once-weekly injection
  • Effectiveness: 15% average weight loss in clinical trials (STEP 1)
  • Best for: People whose insurance covers weight loss medications
  • ### 2. Zepbound (Tirzepatide) Zepbound targets both GLP-1 and GIP receptors, a dual mechanism that may produce even greater weight loss.

  • Cost: $1,060/month without insurance
  • How it's taken: Once-weekly injection
  • Effectiveness: Up to 20.9% average weight loss in SURMOUNT trials
  • Best for: People looking for the newest, most potent option (if cost isn't a barrier)
  • ### 3. Mounjaro (Tirzepatide) Same medication as Zepbound but FDA-approved for type 2 diabetes. Sometimes prescribed off-label for weight loss.

  • Cost: $1,069/month without insurance
  • Note: Faces periodic shortages, like Ozempic
  • ### 4. Compounded Semaglutide Contains the exact same active ingredient as Ozempic and Wegovy, prepared by FDA-registered compounding pharmacies.

  • Cost: $179-$299/month, roughly 80% less than brand names
  • How it's taken: Once-weekly injection
  • Effectiveness: Same as brand-name semaglutide
  • Best for: Most people paying out of pocket
  • Available at: Majesta Health starting at $179/month
  • ### 5. Compounded Tirzepatide Offers the dual GLP-1/GIP agonist at a reduced cost.

  • Cost: Typically $350-$500/month
  • Best for: People who want the dual-mechanism medication but can't afford Zepbound
  • ### 6. Over-the-Counter Supplements (Not a Replacement) You'll see many OTC supplements claiming to be "natural Ozempic alternatives." Be cautious, these are not FDA-approved for weight loss and no supplement can replicate the effects of prescription GLP-1 medications.

    Comparison at a Glance

    | Option | Monthly Cost | Effectiveness | Availability | |---|---|---|---| | Ozempic | $935 | 15% avg weight loss | Limited (shortages) | | Wegovy | $1,349 | 15% avg weight loss | Moderate | | Zepbound | $1,060 | Up to 20.9% avg weight loss | Improving | | Compounded semaglutide | $179-$299 | Same as Ozempic/Wegovy | Good | | Compounded tirzepatide | $350-$500 | Same as Zepbound/Mounjaro | Good |

    Which Alternative Is Right for You?

    If your insurance covers weight loss medications: Wegovy or Zepbound may be your best option.

    If you're paying out of pocket: Compounded semaglutide offers the best value, the same active ingredient at roughly 80% less cost. At Majesta Health, it starts at just $179 for the first month.

    If you want the latest dual-agonist technology: Consider compounded tirzepatide or Zepbound, depending on your budget.

    The Bottom Line

    Ozempic isn't the only option, and for many people, it may not be the best one.

    Ready to explore your options? Take our free 2-minute assessment to connect with a board-certified physician.


    This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider. Individual results may vary. Clinical data referenced from STEP and SURMOUNT trials published in The New England Journal of Medicine.

    Ready to Reserve Your Spot?

    Join the founding-member waitlist for priority access and locked-in pricing.

    Join the Waitlist